Abstract: 【Abstract】 Objective To explore the clinical efficacy of transcatheter hepatic arterial embolization （TACE） in treatment of patients with liver metastasis from colon-rectal cancer. Methods90patients with liver metastasis from colon-rectal cancer in our hospital between November2013, November2014were recruited, and they were randomly divided into observation group, control group. The patients in both groups were treated with TACE, and the only difference was arterial infusion of raltitrexed in the observation group. Clinical efficacy, serum CA19-9, CEA levels, adverse events, long-term survival rates were observed, recorded in the two groups. Results The total effective rate in the observation group was51.1%, significantly higher than22.2% in the control group（P<0.05）;before treatment, there were no significant differences as respect to serum CA19-9, CEA levels between the two groups （P>0.05）, while three months after treatment, serum CA19-9, CEA levels in the observation group were （18.46±7.59） U/ml, （3.52±2.58） ng/ml, significantly lower than [（27.65±11.85） U/ml and（9.86±3.47） ng/ml, respectively, in the control group, P<0.05];the incidence of adverse reactions was22.2% in the observation group, significantly lower than46.7% in the control group （P<0.05）;the1a, 2a, 3a survival rates in the observation group was88.9%, 73.3%, 57.8%, respectively, obviously higher than66.7%, 42.2%, 33.3% in the control group （P<0.05）. Conclusion The application of raltitrexed in TACE treatment of patients with liver metastasis from colon-rectal cancer can effectively improve patients' clinical efficacy, prolong the long-term survivals

Key words: Liver metastasis, Transcatheter hepatic arterial embolization, Raltitrexed, Therapy